- Home
- TAK vs KVUE Comparison
TAK vs KVUE Comparison
Compare TAK & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAK
- KVUE
- Stock Information
- Founded
- TAK 1781
- KVUE 2022
- Country
- TAK Japan
- KVUE United States
- Employees
- TAK N/A
- KVUE N/A
- Industry
- TAK Biotechnology: Pharmaceutical Preparations
- KVUE Specialty Chemicals
- Sector
- TAK Health Care
- KVUE Consumer Discretionary
- Exchange
- TAK Nasdaq
- KVUE Nasdaq
- Market Cap
- TAK 47.0B
- KVUE 43.6B
- IPO Year
- TAK N/A
- KVUE 2023
- Fundamental
- Price
- TAK $14.37
- KVUE $24.46
- Analyst Decision
- TAK
- KVUE Buy
- Analyst Count
- TAK 0
- KVUE 12
- Target Price
- TAK N/A
- KVUE $24.92
- AVG Volume (30 Days)
- TAK 2.0M
- KVUE 19.6M
- Earning Date
- TAK 05-08-2025
- KVUE 05-08-2025
- Dividend Yield
- TAK 4.08%
- KVUE 3.37%
- EPS Growth
- TAK N/A
- KVUE N/A
- EPS
- TAK 0.45
- KVUE 0.54
- Revenue
- TAK $30,595,075,281.00
- KVUE $15,455,000,000.00
- Revenue This Year
- TAK $0.87
- KVUE $1.81
- Revenue Next Year
- TAK $1.69
- KVUE $4.00
- P/E Ratio
- TAK $63.69
- KVUE $45.28
- Revenue Growth
- TAK 7.45
- KVUE 0.07
- 52 Week Low
- TAK $12.58
- KVUE $17.67
- 52 Week High
- TAK $15.37
- KVUE $25.17
- Technical
- Relative Strength Index (RSI)
- TAK 40.48
- KVUE 62.20
- Support Level
- TAK $14.22
- KVUE $23.01
- Resistance Level
- TAK $15.43
- KVUE $25.17
- Average True Range (ATR)
- TAK 0.20
- KVUE 0.64
- MACD
- TAK -0.08
- KVUE 0.11
- Stochastic Oscillator
- TAK 11.98
- KVUE 74.51
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
About KVUE Kenvue Inc.
Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.